Pediatric central nervous system primitive neuro-ectodermal brain tumors (CNS-PNETs) are rare tumors with ill-defined biological features. In this issue of Cell, Sturm et al. used state-of-the-art methods to interrogate these tumors' biology. Their integrated molecular analyses led them to propose a new molecular classification, with four new entities identified, that should get oncologists' attention.
Central nervous system primitive neuroectodermal brain tumors (CNS-PNETs) are a heterogeneous group of CNS neoplasms that are composed of poorly differentiated neuroepithelial cells that display differentiation spectrum along neuronal, astrocytic, and ependymal lines. Excluding medulloblastomas, they account for 3%-5% of childhood brain tumors. Clinical features that are common to all CNS-PNET variants include aggressive clinical behavior and poor outcome (Jakacki et al., 2015) .
Traditionally, most treatment trials for CNS-PNET have adopted strategies similar to high-risk medulloblastoma. Currently, the outcome for children with CNS-PNETs is poor, with a 5 year overall survival rate of 48% to 73% (Massimino et al., 2013; Jakacki et al., 2015) . The influence of factors such as metastatic disease, resection extent, histological features, and biological characteristics on treatment is currently unclear. Local failure has been a common theme in clinical trials. This lack of knowledge hinders the development of more effective treatments.
To provide a concerted molecular analysis of the largest number of CNS-PNETs to date, Sturm et al. (2016) undertook a multicenter international collaboration in which they conducted integrated genomic analyses of 323 CNS-PNET patients. In doing so, they were able to substantially extend prior efforts to elucidate the genetic characteristics of CNSPNETs and identify molecular subgroups. Picard et al. (2012) identified three molecular subgroups of CNS-PNETs that were distinguished by primitive neural (group 1), oligoneural (group 2), and mesenchymal lineage (group 3) gene expression signatures with differential expression of LIN28 and OLIG2. Patients in group 1 had the poorest survival, while those in group 3 had the best survival. Behdad and Perry (2010) found that both anaplastic/large cell features and polysomies of chromosomes 2 and 8 were associated with more aggressive clinical behavior. Amplification of MYCN, C19MC, and PDGFRA/B; deletions of CDKN2A/2B; activation of the WNT/ b-catenin pathway; mutation of H3.3 G34R; and a few other sporadic alterations had also been reported to have prognostic implications (Miller et al., 2011; Picard et al., 2012; von Bueren et al., 2012) . Sturm et al. (2016) generated genome-wide DNA methylation profiles of the CNS-PNET samples and compared them to those of 211 wellcharacterized reference tumors of 19 other CNS tumor entities, through unsupervised clustering. CNS-PNETs did not form a uniform cluster but mostly grouped with clusters of the reference tumor entities in 61% of the samples. Strikingly, patients' information (age at diagnosis, tumor location, and survival) from the aforementioned clusters matched the clinical features of the reference entities and subgroups; this may have future therapeutic implications. Remarkably, 31% of the CNSPNETs in the current study have biology similar to high-grade glioma (HGG), which begs the question if there a therapeutic role of temozolomide, histone deacetylases inhibitors, Aurora kinase inhibitors, and demethylating agents, which are active in HGG (Vanan and Eisenstat, 2014) .
This study redefines the current histological diagnosis, indicating that CNSPNETs represent morphological variants of other histologically and molecularly defined diagnostic entities (Figure 1) . It also adds 4 new CNS entities (24% of the cohort) with well-defined genetic alterations and clinical features: CNS neuroblastoma with FOXR2 activation (CNS NB-FOXR2), CNS Ewing sarcoma family tumor with CIC alteration (CNS EFT-CIC), CNS high-grade neuroepithelial tumor with MN1 alteration (HGNET-MN1), and CNS high-grade neuroepithelial tumor with BCOR alteration (CNS HGNET-BCOR). In the CNS NB-FOXR2 entity, fusions involving JMJD1C were identified, a histone demethylase that is required for the survival in acute myeloid leukemia, testicular, and gastric cancer. JMJD1C functions as a transcription coactivator (Chen et al., 2015) , and its inhibition could be pursued in the future. Similarly, for the CNS EFT-CIC entity, translocations involving NUT gene were identified that are noteworthy because bromodomain-containing protein 4 (BRD4) -NUT translocations are seen in Nut-midline carcinomas and are sensitive to bromodomain inhibitors. Furthermore, MN1 translocations were identified in the HGNET-MN1 entity, previously identified as well in leukemia and meningiomas (Langer et al., 2009 ). MN1 is a transcription coregulator that alters gene transcription; further analysis is needed to reveal if there is common deregulated signaling across these tumor types. The CNS HGNET-BCOR subgroup shows pathway activation of both BCL6 and Wnt, which can be targeted by small molecules already in clinical trials. An obvious question is whether the genetic aberrations identified in the four new entities are oncogenic or not: this will require validation in order for therapeutic potential to be realized.
An intriguing observation is that 15% of these tumors did not cluster with any of the 19 CNS entities on the panel and were identified as CNS embryonal tumors NOS. This raises the interesting question of whether that 15% may cluster with other tumor entities that were not included in the reference panel. The new study represents a significant landmark in critical ongoing efforts to revolutionize the current management for CNS-PNETs. In the era of personalized therapy, there is a dire need to combine both histological and molecular markers into the upfront diagnosis, which may represent a significant step toward improved patient stratification and riskadapted therapeutic strategies. CNS PNETs are a heterogeneous group and, hence, should not be treated uniformly, an approach that is resulting in unpredictable treatment failure. The formidable task lies in validation of these molecular classifications and the ability to correlate them with clinical outcomes in order to profile novel and effective therapies. Given the relatively low frequency of the disease, probing the value of separating CNS-PNETs into different treatment groups based on underlying biology for clinical trials will require multi-institutional collaboration. The expansion of current knowledge and its potential for improving treatment strategies provides is a reason for cautious optimism for clinical management of pediatric CNS-PNETs.
